Anti-Human EGFR – DyLight® 650
Anti-Human EGFR – DyLight® 650
Product No.: E329
- -
- -
Clone EGFR.1 Target EGFR Formats AvailableView All Product Type Monoclonal Antibody Alternate Names ERBB, ERBB1, mENA,Epidermal Growth Factor Receptor Isotype IgG2b κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen Purified Recombinant Human EGFR (>98%) Product Concentration 0.2 mg/ml Formulation This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (652 nm) RRIDAB_2830089 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone EGFR.1 recognizes the human EGFR. Background EGFR is a 170 kD transmembrane glycoprotein that is part of the ErbB family of receptors within the protein kinase superfamily. EGFR is one of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR is essential for various processes including controlling cell growth and differentiation and ductal development of the mammary glands. Ligand binding induces dimerization and autophosphorylation. It consists of a glycosylated extracellular domain which binds to EGF and an intracellular domain with tyrosine-kinase activity necessary for signal transduction. TGFα, vaccinia virus growth factor, and related growth factors can also bind to and signal through EGFR. Abnormal EGFR signaling has been implicated in inflammatory diseases such as psoriasis, eczema and atherosclerosis. Alzheimer's disease is linked with poor signaling of the EGFR and other receptor tyrosine kinases. Furthermore, over-expression of the EGFR is linked with the growth of various tumors. EGFR has been identified as an oncogene, a gene which in certain circumstances can transform a cell into a tumor cell, which has led to the therapeutic development of anticancer EGFR inhibitors. EGFR is a well-established target for both mAbs and specific tyrosine kinase inhibitors. PubMed NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology . Innate Immunity . Neuroscience . Synaptic Biology References & Citations1. Berger, SM. et al. (1987) J. of Pathology 152:297 2. Downward, J. et al. (1984) Nature 311:483 3. Gullick, WJ. et al. (1985) EMBO J. 4:2869 4. Gullick, WJ. et al. (1986) Cancer Research 46:285 5. Gullick, WJ. et al. (1991) Br. Med. Bulletin 47:87 Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
E333 | |
E325 | |
E326 | |
E327 | |
E329 | |
E331 | |
E336 | |
E101 | |
E337 | |
E100 |
![Disclaimer Alert Disclaimer Alert](/wp-content/themes/Avada-Child-Theme/disclaimer.jpg)